Ironwood Pharma (IRWD) Reports Q1 Lost Per Share of 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Oracle shares drop on AI spending concerns and Microsoft criticism
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Ironwood Pharmaceuticals Provides First Quarter 2015 Investor Update
May 5, 2015 4:02 PM EDTLINZESS® (linaclotide) U.S. net sales of $95.5 million in first quarter 2015
Total LINZESS prescriptions increased approximately 90% in first quarter 2015 compared to first quarter 2014
Reported positive top-line data from IW-3718 Phase IIa study for refractory GERD
Advanced sGC platform with initiation of first candidate, IW-1973, into Phase I study
Established agreement with Exact Sciences to co-promote Cologuard®
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More



